| Company Name: | Aventis | | Ticker Symbol: | AVE | | | WWW Address: | www.aventis.com | | CEO: | Patrick Langlois | | No. of Employees: | 75,567 | | Common Issue Type: | AD | | Business Description: | A global pharmaceutical company that discovers, develops, manufactures and markets branded prescription drugs and human vaccines to protect and improve the health of patients around the world.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | |  | - | - | 0 | 94.65 | 93.90 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 75,647.3 | 805.6 | 0.27 | 3.04 | 0.75 | 28.6 | 1.0 | 94.98 - 64.51 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 93.90 | $ | | PE Ratio - LTM | 28.6 | |
| Market Capitalisation | 75,647.3 | mil |
| Latest Shares Outstanding | 805.6 | mil |
| Earnings pS (EPS) | 3.04 | $ |
| Dividend pS (DPS) | 0.75 | ¢ |
| Dividend Yield | 1.0 | % |
| Dividend Payout Ratio | 25 | % |
| Revenue per Employee | 296,386 | $ |
| Effective Tax Rate | 31.9 | % |
| Float | 805.6 | mil |
| Float as % of Shares Outstanding | 100.0 | % |
| Foreign Sales | 15,452 | mil |
| Domestic Sales | 6,945 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 16.00 | % |
| Gross Profit Margin | 76.9 | % |
| EBITDA Margin | 24.3 | % |
| Pre-Tax Profit Margin | 15.9 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 7.9 | % |
| Return on Equity (ROE) | 20.9 | % |
| Return on Capital Invested (ROCI) | 15.2 | % |
| Current Ratio | 1.1 | |
| Leverage Ratio (Assets/Equity) | 2.6 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.40 | |
| LT Debt/Total Capital | 22.0 | % |
| Working Capital pS | 1.49 | $ |
| Cash pS | 2.65 | $ |
| Book-Value pS | 15.78 | $ |
| Tangible Book-Value pS | 1.51 | $ |
| Cash Flow pS | 5.48 | $ |
| Free Cash Flow pS | 1.62 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 5.95 | |
| Price/Tangible Book Ratio | 62.19 | |
| Price/Cash Flow | 17.1 | |
| Price/Free Cash Flow | 58.0 | |
| P/E as % of Industry Group | 93.0 | % |
| P/E as % of Sector Segment | 139.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | Cash Payment |
| Dividend Rate | 0.98 |
| Current Dividend Yield | 1.0 |
| 5-Y Average Dividend Yield | 0.9 |
| Payout Ratio | 25.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 101 | 225 | 0 |
| 4 Weeks | 94.98 | 87.30 | 86.99 | 7.9 | 107 | 217 | 3,249 |
| 13 Weeks | 94.98 | 81.25 | 83.17 | 12.9 | 105 | 357 | 21,073 |
| 26 Weeks | 94.98 | 74.98 | 78.95 | 18.9 | 110 | 623 | 76,654 |
| 52 Weeks | 94.98 | 64.51 | 65.80 | 42.7 | 133 | 2,603 | 642,974 |
| YTD | 0.00 | 0.00 | - | 0.0 | 101 | 0 | 0 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 94.34 | 93.36 | 89.39 | 83.39 | 81.56 | 0.27 | 0.72 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 9.84 | 63.4 | 2.89 |
| Income | 0.00 | 0.0 | 70.56 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 2.16 | NA | -1.45 |
| R&D | 0.00 | NA | 5.02 |
| Normalized Inc. | 0.00 | NA | -2.73 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 0.5 | -2.1 | 3.4 |
| Earnings % | 47.8 | -0.6 | 7.4 |
| EPS % | 54.2 | 3.4 | 9.7 |
| EPS $ | 0.64 | 0.03 | 0.27 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 2.19 |
| Current Ratio | 1.1 |
| Quick Ratio (Acid Test) | 0.4 |
| Liquidity Ratio (Cash) | 0.12 |
| Receivables Turnover | 0.0 |
| Average Collection Period | 0 |
| Working Capital/Equity | 6.1 |
| Working Capital pS | 0.97 |
| Cash-Flow pS | 5.51 |
| Free Cash-Flow pS | -0.68 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 3.16 |
| Financial Leverage Ratio (Assets/Equity) | 2.8 |
| Debt Ratio | 63.1 |
| Total Debt/Equity (Gearing Ratio) | 0.50 |
| LT Debt/Equity | 0.31 |
| LT Debt/Capital Invested | 63.9 |
| LT Debt/Total Liabilities | 17.7 |
| Interest Cover | 8.3 |
| Interest/Capital Invested | 2.06 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 56.93 |
| Tobin's Q Ratio | 2.13 |
| Current P/E Ratio - LTM | 28.60 |
| Enterprise Value (EV)/EBITDA | 17.36 |
| Enterprise Value (EV)/Free Cash Flow | -178.77 |
| Dividend Yield | 1.0 |
| Price/Tangible Book Ratio - LTM | 62.19 |
| Price/Book Ratio - LTM | 5.95 |
| Price/Cash Flow Ratio | 17.1 |
| Price/Free Cash Flow Ratio - LTM | 58.0 |
| Price/Sales Ratio | 3.28 |
| P/E Ratio (1 month ago) - LTM | 27.2 |
| P/E Ratio (26 weeks ago) - LTM | 26.0 |
| P/E Ratio (52 weeks ago) - LTM | 31.6 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 93.0 |
| P/E as % of Sector Segment | 139.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 25.5 |
| PER SHARE FIGURES |
| LT Debt pS | 4.95 |
| Current Liabilities pS | 14.35 |
| Tangible Book Value pS - LTM | 1.51 |
| Book Value pS - LTM | 15.78 |
| Capital Invested pS | 21.21 |
| Cash pS - LTM | 2.65 |
| Cash Flow pS - LTM | 5.48 |
| Free Cash Flow pS - LTM | 1.62 |
| Earnings pS (EPS) | 3.04 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -2.42 |
| Free Cash Flow Margin 5YEAR AVG | -0.51 |
| Net Profit Margin | 11.0 |
| Net Profit Margin - 5YEAR AVRG. | 5.4 |
| Equity Productivity | 1.77 |
| Return on Equity (ROE) | 19.4 |
| Return on Equity (ROE) - 5YEAR AVRG. | 9.8 |
| Capital Invested Productivity | 1.31 |
| Return on Capital Invested (ROCI) | 14.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 6.6 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | 6.9 |
| Return on Assets (ROA) - 5YEAR AVRG. | 2.9 |
| Gross Profit Margin | 76.9 |
| Gross Profit Margin - 5YEAR AVRG. | 71.0 |
| EBITDA Margin - LTM | 24.3 |
| EBIT Margin - LTM | 18.0 |
| Pre-Tax Profit Margin | 16.3 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 9.4 |
| Effective Tax Rate | 31.9 |
| Effective Tax Rate - 5YEAR AVRG. | -26.7 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 48 |
| Revenue per Employee | 296,386 |
| Net Income per Employee | 32,488 |
| Average Collection Period | 48 |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 11.1 |
| Accounts Payble/Sales | 7.42 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 28.82 |
| Fixed Assets Turnover | 0.96 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 28.68 |
| Revenue per $ Plant | 4.31 |
| Revenue per $ Common Equity | 1.77 |
| Revenue per $ Capital Invested | 1.31 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 34.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 36.1 |
| Research & Devlopment (R&D) as % of Revenue | 16.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 16.4 |
|
|  
|
| |
 |  |